GC Biopharma, a South Korean biopharmaceutical company, has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets. Amezosvatein is an adjuvanted recombinant protein vaccine, similar in format to GSK’s Shingrix, but...